There are currently 73 clinical trials in Mckinney, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including Texas Oncology- Mckinney, North Dallas Research Associates, Novartis Investigative Site and Metroplex Pulmonary and Sleep Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
NCT05918861
Recruiting
This is a placebo-controlled, randomized, double-blind, parallel group, phase 3 multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will provide informed consent before any study-specific procedures are performed. A separate informed consent will be allowed for an initial pre-screening genetic testing. Subjects meeting the AA genotype will then consent to the full study and confirmatory genetic testing as required. Subject enrollment may... Read More
Gender:
All
Ages:
45 years and above
Trial Updated:
04/12/2024
Locations: Research Site, McKinney, Texas
Conditions: Acute Coronary Syndrome
Register for Updates
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
NCT06097260
Recruiting
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF).
Gender:
All
Ages:
40 years and above
Trial Updated:
04/11/2024
Locations: Metroplex Pulmonary and Sleep Medicine Center, McKinney, Texas +1 locations
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
NCT04961996
Recruiting
This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with endocrine therapy of physician's choice in participants with medium- and high-risk Stage I-III histologically confirmed estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. In addition, an open-label exploratory substudy will explore the safety and efficacy of giredestrant in combination wit... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/10/2024
Locations: Texas Oncology McKinney, McKinney, Texas
Conditions: Early Breast Cancer
Register for Updates
Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States
NCT05329194
Recruiting
To asses effectiveness and safety of tezepelumab in adult and adolescent participants with severe asthma including several under-studied populations in the United States.
Gender:
All
Ages:
Between 12 years and 130 years
Trial Updated:
04/10/2024
Locations: Research Site, McKinney, Texas
Conditions: Asthma
Register for Updates
Development and Validation of Harbinger Health Test for Early Cancer Detection
NCT05435066
Recruiting
This is a prospective, multi-center, observational study with a collection of biospecimens and clinical data from approximately 10,000 participants from up to 125 clinical network sites and locations in the United States. The objective of this study is to collect blood samples, tissue samples, and associated clinical data from participants with a variety of solid tumor and hematologic cancers and non-cancer participants for testing and the development of a screening test for early cancer detecti... Read More
Gender:
All
Ages:
Between 20 years and 79 years
Trial Updated:
04/09/2024
Locations: Texas Oncology - Northeast Texas Cancer and Research, McKinney, Texas
Conditions: Cancer
Register for Updates
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
NCT05975983
Recruiting
The goal of this clinical trial is to learn about INS018_055 in adults with Idiopathic Pulmonary Fibrosis (IPF). The primary objective is to evaluate the safety and tolerability of INS018_055 orally administered for up to 12 weeks in adult subjects with IPF compared to placebo.
Gender:
All
Ages:
40 years and above
Trial Updated:
04/09/2024
Locations: Metroplex Pulmonary and Sleep Center, McKinney, Texas +1 locations
Conditions: Idiopathic Pulmonary Fibrosis (IPF)
Register for Updates
Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
NCT02446132
Recruiting
This is an extension study of the Phase 3 Studies 15-AVP-786-301, 15-AVP-786-302, and 17-AVP-786-305, which also allows participants from the Phase 2 Study 12-AVR-131 to be included.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
04/05/2024
Locations: Wellness Clinical Research Site #824, McKinney, Texas
Conditions: Agitation in Patients With Dementia of the Alzheimer's Type
Register for Updates
A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
NCT05037929
Recruiting
This study will evaluate the efficacy, safety, and pharmacokinetics of astegolimab in combination with standard of care chronic obstructive pulmonary disease (COPD) maintenance therapy in patients with COPD who are former or current smokers and have a history of frequent exacerbations.
Gender:
All
Ages:
Between 40 years and 90 years
Trial Updated:
04/05/2024
Locations: Metroplex Pulmonology & Sleep Center, McKinney, Texas
Conditions: Chronic Obstructive Pulmonary Disease
Register for Updates
Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma
NCT05251259
Recruiting
This is a randomised, placebo-controlled, double-blind study to assess the efficacy and safety of Atuliflapon administered once daily over a 12-week treatment period to adult participants with moderate to severe uncontrolled asthma.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/05/2024
Locations: Research Site, McKinney, Texas
Conditions: Asthma
Register for Updates
Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)
NCT04652882
Recruiting
This is a multicenter, double-blind, randomized study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon and matching placebo in male and female participants with DSWPD.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/01/2024
Locations: Vanda Investigational Site, McKinney, Texas
Conditions: Sleep Wake Disorders, Sleep Disorders, Circadian Rhythm, Chronobiology Disorders
Register for Updates
Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies
NCT06005597
Recruiting
The study is a placebo-controlled, double-blind, randomized, phase 3 study in participants with heterozygous familial hypercholesterolemia (HeFH) and/or atherosclerotic cardiovascular disease (ASCVD) or multiple ASCVD risk factors to evaluate the efficacy, safety and tolerability of obicetrapib 10mg and ezetimibe 10mg fixed dose combination as an adjunct to diet and maximally tolerated lipid-lowering therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: Wellness Clinical Research Associates, McKinney, Texas
Conditions: Dyslipidemias, Hypercholesterolemia, Familial Hypercholesterolemia, ASCVD, High Cholesterol
Register for Updates
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
NCT05636176
Recruiting
This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get ziltivekimab or placebo. Participants will get study medicine for once-monthly injections either in a pre-filled syringe to inject the study medicine into a skinfold or a pen-injector to inject the study medicine into flat skin. The study is expected to last for up to 4 years. Participants will have up to 20 clinic visits. Participants will have to u... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/31/2024
Locations: Texas Institute of Cardiology PA, McKinney, Texas
Conditions: Heart Failure
Register for Updates